Notice: Images are for illustration only and may not reflect the exact product you receive. Brand-name medications may look different depending on their country of origin—Canadian versions, for example, often include a "PR" symbol on the packaging. Rest assured, the medication, dosage, and active ingredients will be exactly as prescribed. Canada Pharmacy Store is committed to your health and safety, and we work only with licensed pharmacies to ensure you receive trusted, high-quality medication every time.
General Medication Fact Sheet for Ilumya
| Field | Information |
|---|---|
| Medication Name | Ilumya |
| Generic Name | Tildrakizumab-asmn |
| Purpose | Treatment of moderate-to-severe plaque psoriasis in adults |
| Mechanism of Action | Selective interleukin-23 (IL-23) inhibitor, binds to the p19 subunit of IL-23, inhibiting its interaction with the IL-23 receptor |
| Dosage Forms | Subcutaneous injection |
| Available Strengths | 100 mg/mL |
| Dosage Frequency | Initial doses at Week 0 and Week 4, then every 12 weeks |
| Common Side Effects | Upper respiratory infections, injection site reactions, headache, diarrhea |
| Serious Side Effects | Serious allergic reactions, infections (e.g., tuberculosis) |
| Drug Interactions | Live vaccines (avoid use) |
| Important Notes | May increase your risk of infections; consult a doctor if signs of an infection develop |
| Storage | Store in the refrigerator at 2-8°C (36-46°F) in the original carton to protect from light. Do not freeze. |
| Missed Dose | Administer the dose as soon as you remember, then continue with your regular dosing schedule. |
| Alternatives | Stelara (ustekinumab), Cosentyx (secukinumab), Tremfya (guselkumab), Skyrizi (risankizumab-rzaa) |
Ilumya Alternatives
| Medication | Mechanism of Action | Notes |
|---|---|---|
| Stelara (ustekinumab) | IL-12 and IL-23 antagonist | Given as a subcutaneous injection. |
| Cosentyx (secukinumab) | IL-17A inhibitor | Given as a subcutaneous injection. |
| Tremfya (guselkumab) | IL-23 inhibitor | Given as a subcutaneous injection. |
| Skyrizi (risankizumab-rzaa) | IL-23 inhibitor | Given as a subcutaneous injection. |
Ilumya Side Effects
| Common Side Effects | Serious Side Effects |
|---|---|
| Upper respiratory infections (e.g., common cold) | Serious allergic reactions (e.g., angioedema, urticaria) |
| Injection site reactions (pain, redness, swelling) | Increased risk of infections, including tuberculosis |
| Headache | Worsening of Crohn’s disease |
Ilumya Dosage Guide
| Condition | Starting Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|
| Plaque Psoriasis | 100 mg | 100 mg every 12 weeks after initial doses at Week 0 and Week 4 | Administered as a subcutaneous injection. Rotate injection sites. |
Ilumya Price With And Without Insurance
| Purchase Context | Estimated Price |
|---|---|
| With Insurance | $500 |
| Without Insurance (U.S.) | $21,000 |
| From Canada | $16,000 |
